Class information for:
Level 1: TUMOR IMMUNOL BIOL//SIPULEUCEL T//5T4

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
13629 823 48.4 87%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
10 3       IMMUNOLOGY//JOURNAL OF IMMUNOLOGY//IMMUNOL 134299
140 2             IMMUNOTHERAPY//DENDRITIC CELLS//CANCER IMMUNOLOGY IMMUNOTHERAPY 23462
13629 1                   TUMOR IMMUNOL BIOL//SIPULEUCEL T//5T4 823

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 TUMOR IMMUNOL BIOL address 1833849 19% 32% 155
2 SIPULEUCEL T authKW 957348 6% 56% 46
3 5T4 authKW 439348 2% 79% 15
4 5T4 ONCOFETAL ANTIGEN authKW 371011 1% 100% 10
5 PROVENGE authKW 237444 1% 80% 8
6 PROSTVAC authKW 227242 1% 88% 7
7 TROVAX authKW 227242 1% 88% 7
8 TRICOM authKW 215856 1% 73% 8
9 PROSTVAC VF authKW 185505 1% 100% 5
10 THERAPEUTIC CANCER VACCINE authKW 184398 2% 38% 13

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Oncology 8415 52% 0% 429
2 Immunology 2802 29% 0% 237
3 Urology & Nephrology 2083 15% 0% 125
4 Medicine, Research & Experimental 1259 15% 0% 127
5 Biotechnology & Applied Microbiology 304 9% 0% 78
6 Endocrinology & Metabolism 45 4% 0% 34
7 Pharmacology & Pharmacy 20 6% 0% 47
8 Hematology 4 2% 0% 13
9 Genetics & Heredity 4 2% 0% 20
10 Andrology 1 0% 0% 1

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 TUMOR IMMUNOL BIOL 1833849 19% 32% 155
2 MEDAWAR 174563 2% 24% 20
3 CLIN IMMUNOTHER Y GRP 103054 1% 56% 5
4 JR GRP VIROL IMMUNOL 98934 0% 67% 4
5 CRC IMMUNOL GRP 74202 0% 100% 2
6 LIFE UNIV CLIN GROSSHADERN 74202 0% 100% 2
7 MED ONCOL BRANCH 57350 4% 5% 34
8 CR UK IMMUNOL GRP 55649 0% 50% 3
9 ONYVAX LTD 55643 1% 25% 6
10 CRUK IMMUNOL 49467 0% 67% 2

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 CANCER IMMUNOLOGY IMMUNOTHERAPY 24885 7% 1% 54
2 EXPERT REVIEW OF VACCINES 10738 2% 2% 19
3 CLINICAL CANCER RESEARCH 8369 7% 0% 58
4 CURRENT OPINION IN MOLECULAR THERAPEUTICS 8302 2% 2% 14
5 JOURNAL OF IMMUNOTHERAPY 7120 2% 1% 18
6 PROSTATE 6835 4% 1% 29
7 CANCER IMMUNOLOGY RESEARCH 6675 1% 2% 9
8 EXPERT OPINION ON BIOLOGICAL THERAPY 6380 2% 1% 19
9 IMMUNOTHERAPY 5133 1% 1% 10
10 UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS 4996 2% 1% 16

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 SIPULEUCEL T 957348 6% 56% 46 Search SIPULEUCEL+T Search SIPULEUCEL+T
2 5T4 439348 2% 79% 15 Search 5T4 Search 5T4
3 5T4 ONCOFETAL ANTIGEN 371011 1% 100% 10 Search 5T4+ONCOFETAL+ANTIGEN Search 5T4+ONCOFETAL+ANTIGEN
4 PROVENGE 237444 1% 80% 8 Search PROVENGE Search PROVENGE
5 PROSTVAC 227242 1% 88% 7 Search PROSTVAC Search PROSTVAC
6 TROVAX 227242 1% 88% 7 Search TROVAX Search TROVAX
7 TRICOM 215856 1% 73% 8 Search TRICOM Search TRICOM
8 PROSTVAC VF 185505 1% 100% 5 Search PROSTVAC+VF Search PROSTVAC+VF
9 THERAPEUTIC CANCER VACCINE 184398 2% 38% 13 Search THERAPEUTIC+CANCER+VACCINE Search THERAPEUTIC+CANCER+VACCINE
10 CANCER VACCINE 127047 8% 5% 64 Search CANCER+VACCINE Search CANCER+VACCINE

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 KIM, JW , GULLEY, JL , (2012) POXVIRAL VECTORS FOR CANCER IMMUNOTHERAPY.EXPERT OPINION ON BIOLOGICAL THERAPY. VOL. 12. ISSUE 4. P. 463 -478 49 55% 13
2 LAROCCA, C , SCHLOM, J , (2011) VIRAL VECTOR-BASED THERAPEUTIC CANCER VACCINES.CANCER JOURNAL. VOL. 17. ISSUE 5. P. 359 -371 42 51% 34
3 KIM, DW , KRISHNAMURTHY, V , BINES, SD , KAUFMAN, HL , (2010) TROVAX, A RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS ENCODING 5T4.HUMAN VACCINES. VOL. 6. ISSUE 10. P. 784 -791 32 73% 11
4 TURRIZIANI, M , FANTINI, M , BENVENUTO, M , IZZI, V , MASUELLI, L , SACCHETTI, P , MODESTI, A , BEI, R , (2012) CARCINOEMBRYONIC ANTIGEN (CEA)-BASED CANCER VACCINES: RECENT PATENTS AND ANTITUMOR EFFECTS FROM EXPERIMENTAL MODELS TO CLINICAL TRIALS.RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY. VOL. 7. ISSUE 3. P. 265-296 59 34% 12
5 MOHEBTASH, M , TSANG, KY , MADAN, RA , HUEN, NY , POOLE, DJ , JOCHEMS, C , JONES, J , FERRARA, T , HEERY, CR , ARLEN, PM , ET AL (2011) A PILOT STUDY OF MUC-1/CEA/TRICOM POXVIRAL-BASED VACCINE IN PATIENTS WITH METASTATIC BREAST AND OVARIAN CANCER.CLINICAL CANCER RESEARCH. VOL. 17. ISSUE 22. P. 7164-7173 28 65% 46
6 MADAN, RA , BILUSIC, M , HEERY, C , SCHLOM, J , GULLEY, JL , (2012) CLINICAL EVALUATION OF TRICOM VECTOR THERAPEUTIC CANCER VACCINES.SEMINARS IN ONCOLOGY. VOL. 39. ISSUE 3. P. 296-304 32 56% 28
7 MADAN, RA , GULLEY, JL , KANTOFF, PW , (2013) DEMYSTIFYING IMMUNOTHERAPY IN PROSTATE CANCER UNDERSTANDING CURRENT AND FUTURE TREATMENT STRATEGIES.CANCER JOURNAL. VOL. 19. ISSUE 1. P. 50-58 35 52% 11
8 SINGH, BH , GULLEY, JL , (2014) IMMUNOTHERAPY AND THERAPEUTIC VACCINES IN PROSTATE CANCER: AN UPDATE ON CURRENT STRATEGIES AND CLINICAL IMPLICATIONS.ASIAN JOURNAL OF ANDROLOGY. VOL. 16. ISSUE 3. P. 364-371 33 53% 7
9 GULLEY, JL , MADAN, RA , TSANG, KY , JOCHEMS, C , MARTE, JL , FARSACI, B , TUCKER, JA , HODGE, JW , LIEWEHR, DJ , STEINBERG, SM , ET AL (2014) IMMUNE IMPACT INDUCED BY PROSTVAC (PSA-TRICOM), A THERAPEUTIC VACCINE FOR PROSTATE CANCER.CANCER IMMUNOLOGY RESEARCH. VOL. 2. ISSUE 2. P. 133 -141 24 63% 26
10 HARROP, R , SHINGLER, W , KELLEHER, M , DE BELIN, J , TREASURE, P , (2010) CROSS-TRIAL ANALYSIS OF IMMUNOLOGIC AND CLINICAL DATA RESULTING FROM PHASE I AND II TRIALS OF MVA-5T4 (TROVAX) IN COLORECTAL, RENAL, AND PROSTATE CANCER PATIENTS.JOURNAL OF IMMUNOTHERAPY. VOL. 33. ISSUE 9. P. 999-1005 20 95% 16

Classes with closest relation at Level 1


Rank Class id link
1 24888 CANC VACCINE DEV//INNOVAT CANC THER Y//PERSONALIZED PEPTIDE VACCINE
2 16780 CANC VACCINE DEV PROGRAM//CANC IMMUNOL IMMUNOTHER Y//TUMOR VACCINE GRP
3 13573 IMMUNOGENIC CELL DEATH//U1015//U805
4 26564 RAS DERIVED PEPTIDES//P53 PEPTIDES//RAS PEPTIDES
5 25112 GV1001//PA MSHA VACCINE//HTERTC27
6 1969 CABAZITAXEL//ABIRATERONE//CASTRATION RESISTANT PROSTATE CANCER
7 8124 TUMOR VACCINE//GENE THERAPY//B71
8 1375 CANCER TESTIS ANTIGEN//NY ESO 1//MAGE
9 33335 STEAP1//STEAP4//STAMP2
10 643 DENDRITIC CELLS//IMMUNOTHERAPY//TUMOR LYSATE

Go to start page